Companies › QBiotics Group
1 active drug program in 2 registered trials: 2 Phase 2; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tigilanol Tiglate Protein kinase C (PKC) activator | – | Phase 2 | Head and Neck Cancer; Soft Tissue Sarcoma | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05608876 | Tigilanol Tiglate | Phase 2 | Head and Neck Cancer | Oncology | Jul 2025 |
| NCT05755113 | Tigilanol Tiglate | Phase 2 | Soft Tissue Sarcoma | Oncology | Jan 2027 |
No annotated target.
–
Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics Apollomics Elevar Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.